Login to Your Account



HCV IN FOCUS, PART I

Gilead golden in HCV for now but many others in the wings

By Marie Powers
Staff Writer

Monday, February 3, 2014

Anyone who thought Gilead Sciences Inc. had the hepatitis C virus (HCV) market sewn up with the December 2013 FDA approval of once-daily oral nucleotide analogue sofosbuvir, branded Sovaldi, isn’t taking the long view. Sovaldi is off to a roaring start but, as Leerink Partners LLC analyst Howard Liang observed in a recent HCV industry update, “by our count there are a total of 19 interferon (IFN)-free regimens for which some sustained virological response (SVR, viral cure) data are available.”

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription